JPRN-UMIN000005144已完成未知
Analysis of Effectiveness and Safety of Abatacept in Japanese patients with Rheumatoid Arthritis. - Effectiveness and Safety of Abatacept in Japan
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •A patient who has any of the following will be excluded from the study. 1.When a patient withdraws his or her consent. 2.When a doctor judges a patient not appropriate to join the study. 3.When a patient is pregnant or has possibility to be pregnant. 4.When a patient is under breast-feeding. 5.When a patient is under contraindication of abatacept.
研究者
相似试验
已完成
2 期
Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot StudyJPRN-UMIN000016148Hiroshima liver study group5
已完成
2 期
Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiencyCTLA4 insufficiency or LRBA deficiencyD84.9Immunodeficiency, unspecifiedDRKS00017736niversitätsklinikum Freiburg vertreten durch den Leitenden Ärztlichen Direktor und die Kaufmännische Direktorin20
进行中（未招募）
1 期
Examination of the drug abatacept (administered as syringe under the skin) in patients suffering from CTLA4 insufficiency or LRBA deficienca. Focus of inverstigation: side effects and effects on the clinical symptoms examined.Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiencyMedDRA version: 20.1Level: PTClassification code 10021449Term: Immunodeficiency common variableSystem Organ Class: 10021428 - Immune system disordersEUCTR2019-000972-40-DEniversitätsklinikum Freiburg20
已完成
2 期
Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosisD86.0Sarcoidosis of lungDRKS00011660niversitätsklinikum Freiburg30
进行中（未招募）
1 期
Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosisEUCTR2016-003360-39-DEniversitätsklinikum Freiburg30